ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
rdf:type |
node1 |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
rdf:type |
owl:Thing |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
rdf:type |
prov:Person |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
rdf:type |
foaf:Person |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
owl:sameAs |
https://semopenalex.org/author/A5100309125 |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
foaf:familyName |
Yan |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
foaf:givenName |
Zhenyu |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
foaf:name |
Zhenyu Yan |
ripekg:retraction-notice/7231SPHK1 inhibitor suppresses cell proliferation and invasion associated with the inhibition of NF-kappaB pathway in hepatocellular carcinoma |
ripe:concerns |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
dcterms:creator |
ripekg:author/RIPEAU10D8FF29337AF7EDZhenyu Yan |